• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Pay range for Sr. TAS


<































The rumblings around the KAR-XT data & viability for success are indeed accurate. I’m surprised it’s getting out so quickly. It seems like a CYA situation where no one finds this baby attractive anymore. Cue the blame game. It’s is $14B worth of crap. The architect(s) of this deal must be fired swiftly. Especially the people in access who green lighted this deal. They should have known better. This is pig that will be slaughtered by Medicaid & commercial payers. Geez!